We investigated the possibility of using a pharmacologic agent to modulate viral gene expression to target radiotherapy to tumor tissue. In a mouse xenograft model, we had previously shown targeting of Here we extend those results to targeting of a therapeutic radiopharmaceutical [ 131 I]FIAU to slow or stop tumor growth or to achieve tumor regression. These outcomes were achieved in xenografts with tumors that constitutively expressed the EBV-TK. With naturally infected EBV tumor cell lines (Burkitt's lymphoma and gastric carcinoma), activation of viral gene expression by pretreatment with bortezomib was required. Marked changes in tumor growth could also be achieved in naturally infected Kaposi's sarcoma herpesvirus tumors after pretreatment with bortezomib. Bortezomib-induced enzymetargeted radiation therapy illustrates the possibility of pharmacologically modulating tumor gene expression to result in targeted radiotherapy.
Targeting of radiopharmaceuticals provides a key tool for the therapy of malignancy. Targeting tissue-specific surface antigens such as CD20 on B cells with radioimmunoconjugates has expanded the application of therapeutic radiation 1, 2 . However, radioimmunoconjugates may be limited by the expression level of the target molecules, the affinity of the antibody or the physical characteristics of the antibody (which may impede delivery to large tumors or protected compartments) 3 . Targeting metabolic pathways such as those involved in concentrating iodine in thyroid tissue is an alternative approach, the more general application of which has been limited by the ability to identify appropriate tumor-specific pathways.
EBV is associated with various lymphomas and carcinomas. Kaposi's sarcoma herpesvirus (KSHV, or HHV-8) is associated with sarcoma and lymphoma. These viral genomes serve as nearly tumorspecific targets 4 . Thus, virus-associated metabolic pathways approximate tumor-specific metabolic pathways. The ability to target radioisotopes to herpesvirus pathways has been shown with vectors engineered to encode the herpes simplex 1 (HSV1) thymidine kinase to monitor gene expression in the gene therapy setting 5, 6 . Direct application to virus-associated tumors has been limited by the virtual absence of expression of the thymidine kinase in tumor cells.
We previously showed that naturally occurring tumor cells harboring EBV could be imaged with a radiolabeled nucleoside analogue if a pharmacologic inducer of the viral thymidine kinase was used 7 . In the present investigation, we extend that observation to show that an inducing agent with a radiotherapeutic nucleoside analogue allows targeted therapy of virus-harboring tumor cells in xenograft models.
RESULTS

Engineered constitutive EBV-TK expression
To evaluate specificity with regard to the concentration of FIAU in tumor tissue, we used a human osteosarcoma cell line engineered to express the EBV-TK 8 . Tumor cells were engrafted on the flanks of severe combined immunodeficent (SCID) mice. After the tumors became palpable, [ 125 I]FIAU was administered intravenously, and, at various time points thereafter, mice were killed so that tissue distribution assays could be performed (Fig. 1) . We detected radioactivity in tumor by 2 h after [ 125 I]FIAU administration. The radioactivity in the tumor was stable through the last time point at 96 h, whereas radioactivity in nontarget tissues decreased (Fig. 1) . In a parallel experiment carried out to later time points, the radioactivity in tumor was stable from 2 h until the last time point at 4 d (data not shown). The tumor-to-muscle activity concentration ratio climbed from 4.6 at 2 h after injection to peak at 205 at 24 h and fall to 114 at 96 h, consistent with previous investigators' reports in a similar mouse model with tumors constitutively expressing HSV1-TK 6 .
To determine whether the concentration of the radiopharmaceutical in tumor tissue is adequate to achieve a therapeutic effect, we treated mice with [ 131 I]FIAU or buffered saline. Control and EBV-TK tumors in mice treated with buffered saline and control tumors in mice treated with [ 131 I]FIAU showed similar growth curves. The 95% confidence intervals of the slopes of those growth curves (as determined by linear regression) overlapped (Fig. 2a) (Fig. 2b) . When chimeric tumors were generated from admixtures of EBV-TK and control tumor cells, increasing percentages of EBV-TK-expressing tumor cells in the admixture were associated with increasing sensitivity to [ 131 I]FIAU treatment (Fig. 2c) . Cross-fire, that is, radiation killing of tumor cells that do not harbor the EBV-TK, may be inferred from the substantially slowed tumor growth rate associated with [ 131 I]FIAU treatment of tumor with 10% EBV-TK-expressing cells versus the growth rate associated with 0% EBV-TK-expressing cells (Fig. 2c) . Cell level dosimetry modeling is presented in the online supplementary material ( Supplementary Figs. 1 and 2 online) .
Therapy for EBV-lymphoma and carcinoma
Can a therapeutic effect be achieved in a naturally infected tumor? In previous studies, we identified bortezomib as a potent inducer of lytic EBV infection 7 . To evaluate the specificity of radiopharmaceutical targeting in naturally infected tumor, we engrafted EBV + Burkitt's lymphoma cells subcutaneously on the flanks of SCID mice. Mice with palpable tumors were pretreated with bortezomib and then treated with [ 125 I]FIAU 24 h later. The mice were then killed, and their tissues were assayed for radioactivity. Radioactivity was selectively retained in these tumors (Table 1) . Therefore, we proceeded with an evaluation of a therapeutic isotope (Fig. 3) . As above, mice with Burkitt's lymphoma xenografts were pretreated with either buffer or bortezomib followed by (Fig. 3a) . In experiments with a second EBV + Burkitt's lymphoma cell line (Akata), we achieved parallel results (data not shown). Thus, pretreatment with bortezomib allowed treatment with [ 131 I]FIAU to effectively target tumors.
Although EBV is associated with Burkitt's, AIDS-related, Hodgkin's, NK/T cell and other lymphomas, the most numerically important associations are with nasopharyngeal cancer (B80,000 new cases per year) and approximately 10% of gastric carcinoma (B93,000 new cases per year) [9] [10] [11] . To determine whether the bortezomib-induction strategy might also be applicable to epithelial malignancies, we studied a transplantable human EBV-associated gastric cancer (KT) xenograft 12 . After engraftment, mice were pretreated with bortezomib and then imaged with [ 125 I]FIAU with single-photon emission computed tomography (SPECT; Fig. 4a ). Tissue distribution studies showed selective uptake and retention of [ 125 I]FIAU in tumor, although the ratios between tumor and other tissues were not as pronounced as those seen with the Burkitt's lines ( Table 1) . When pretreatment with bortezomib was followed by [ 131 I]FIAU treatment, tumor growth slowed (Fig. 3b) .
Therapy for KSHV malignancy
Could this approach be extended to KSHV-associated tumors? We studied two primary effusion lymphoma cell lines that harbor KSHV. In a SCID mouse xenograft model, bortezomib treatment allowed imaging of both BCBL1 and BC3 with [ 125 I]FIAU (Fig. 4b) . Tissue distribution studies showed selective uptake and retention in tumor tissue (Table 1) , and, when pretreatment with bortezomib was followed by treatment with [ 131 I]FIAU, tumor growth slowed (Fig. 3c) . 
T E C H N I C A L R E P O R T S DISCUSSION
The HSV1-TK has been a valuable tool in gene therapy approaches 13 . The notion that a viral thymidine kinase might be used to target radiation therapy has been explored by others 14 . Similarly, induction of the EBV-TK with a histone deacetylase inhibitor as pretreatment followed by treatment with ganciclovir has been reported to induce remissions in some individuals 15 . Here, we model a new approach: bortezomib-induced enzyme targeting of radiation (BETR) therapy. We show that this BETR approach yields promising results in lymphoid and epithelial malignancies in murine xenografts of EBVand KSHV-associated human tumors. How do the doses administered in the murine model extrapolate to the clinical setting? Experience with 131 I-labeled antibodies against lymphoma in patients shows that clinical responses are achievable with 0.5-2.0 Gy to the tumor 16 . The biodistribution data from this study allow estimates of the absorbed dose in tumor and vital organs (Supplementary Table 1 online) and suggest that the kidneys and red marrow are the dose-limiting organs for [ 131 I]FIAU. It should be possible to deliver 0.5-2 Gy to a 1-g tumor in a 70-kg individual with critical organ doses well below toxicity. FIAU was previously investigated as an antiviral treatment [17] [18] [19] [20] . Chronic dosing of FIAU was associated with hepatic damage and, in some cases, fatality. In those trials, treatment for o4 weeks with a cumulative dose o200 mg was not associated with either clinical or biochemical evidence of toxicity [17] [18] [19] [20] . Thus, the 'no-effect' dose of FIAU might be conservatively estimated to be on the order of 0.1 mg kg -1 per administration. [ 124 I]FIAU has been administered to individuals for imaging without any adverse effect on hepatic function 21 . Extrapolating from our xenograft experiments, a radiotherapeutic effect is likely to be achieved at doses of FIAU that are several orders of magnitude less than the no-effect FIAU dose in humans.
BETR treatment resulted in uptake and retention of FIAU in lymphoma and carcinoma xenograft models and affected tumor growth curves for each of the tumors studied. However, in the lymphoma models, growth stopped, whereas, in the gastric carcinoma model growth, only seemed to have slowed. This difference probably reflects two phenomena. First, epithelial tumors are more resistant to radiation than lymphoid tumors. Second, the percentage of injected radioactivity per gram of tumor achieved in the lymphomas is greater than in the carcinoma ( Table 1 and Fig. 4) . Optimization for human tumors will ultimately require further xenograft and clinical studies, but the ability to image viral enzyme activation directly in people and thus assess the relevant pharmacokinetics of radiolabeled FIAU offers the promise that optimization can be rapid.
One concern with all 131 I-labeled radiopharmaceuticals is deiodination. In the case of tositumomab, dehalogenases decouple the radioisotope from the antibody moiety, resulting in free, circulating 131 I. To block this accumulation, standard procedure involves pretreatment of patients with thyroid protective agents (potassium iodide) beginning before drug administration and continuing until 2 weeks after administration. In comparison, biotransformation of FIAU is limited because of the high chemical and metabolic stability of the N-glycosyl linkage in pyrimidine nucleosides that contain the 2¢-fluoro substituent in the arabinosyl (up) configuration 22 . Studies of FIAU in serum and whole blood over a 24-h period indicate excellent stability and low susceptibility to deiodination. FIAU is also cleared more rapidly from the plasma than tositumomab (half-life 3.9 h versus 48 h). Thus, [ 131 I]FIAU, given its minimal deiodination and rapid clearance, may be expected to have a better safety profile with respect to radiation exposure in normal tissues than agents already in the clinic. BETR therapy also offers possible advantages over other lytic inductionsuicide prodrug approaches. All lytic induction approaches are limited by the tendency of gammaherpesviruses to become latent. When ganciclovir or a similar agent mediates cell killing, a therapeutic effect might require that a large fraction of tumor cells express viral enzymes. Although the phenomenon of bystander killing attributed to the exchange of phosphorylated nucleotides and nucleotide analogues between cells via gap junctions has been recognized 23 , such killing is limited. In the gene therapy setting, attempts have been made to engineer increased expression of the connexin protein in the gene therapy vector so as to increase bystander killing 24 . However, refined gene therapy vectors are not readily applicable in settings that do not involve gene therapy. Some of the therapeutic agents used to treat tumors may interfere with such connexin-mediated bystander killing 25 A second limitation of the lytic induction-suicide prodrug approaches is that ganciclovir-mediated killing is cell cycle dependent. As reported by several groups of investigators, activation of lytic infection in EBV-or KSHV-infected cells leads to cell cycle arrest [28] [29] [30] , thus probably compromising cell cycle-dependent tumor killing. In contrast, radiation effects are not similarly diminished by lytic induction.
BETR therapy may also offer advantages over radioimmunotherapeutic approaches. Internalization of radioimmunoconjugates may lead to degradation and release of free isotope with a consequent loss of specificity. In contrast, we observed that after injection of [ 125 I]FIAU, the isotope is stably associated with EBV-TK-expressing tumor. Enzymatic phosphorylation and incorporation of FIAU into DNA (as has been reported in HSV1-TK-expressing cells 6 ) offers the possibility of achieving high concentrations in tumor tissue not limited by concentration gradients. Finally, both FIAU and bortezomib are small molecules, and thus better tumor penetration would be anticipated in comparison with antibody conjugates. FIAU does not penetrate the blood-brain barrier but does reach brain tumors, reflecting a disruption of the blood-brain barrier 22 . More broadly, the use of small molecules to activate tissue-or tumor-specific metabolic pathways suggests the possibility that metabolic targeting of radiation may have applications beyond thyroid cancer.
METHODS
Cell lines and plasmids. The Burkitt's lymphoma cell lines Rael and Akata were a gift from S.D. Hayward. The primary effusion lymphoma cell lines BC3 and BCBL1 were a gift from G. Hayward. We maintained lymphoma cell lines in suspension culture in RPMI 1640 (Life Technologies) with 10% FBS, 100 U ml -1 penicillin, 100 mg ml -1 streptomycin and 100 mmol l -1 L-glutamine as previously described 7 . TK-143B and V143B cells are stably transfected lines derived from the human osteosarcoma (143B) cell line carrying either a plasmid expressing EBV-TK or a control vector (PCDNA3), as previously described 8 . These were maintained in DMEM (Life Technologies) supplemented with 10% FBS (Gemini BioProducts), 100 units ml -1 penicillin, 100 Ag ml -1 streptomycin, 2 mmol l -1 L-glutamine and 400 Ag ml -1 G418 for selection. We passaged the KT transplantable EBV + gastric adenocarcinoma in SCID mice 12 7 . For imaging or treatment, we administered FIAU 24 h after bortezomib. In each of the experiments described, we administered bortezomib as a single dose.
Tumor generation. We tested cultured cell lines for mycoplasma and found them to be negative. We resuspended cells (5 Â 10 6 ) in 200 ml Matrigel matrix (BD Biosciences) and injected them subcutaneously into 6-7-week-old male SCID mice (Charles River Laboratories). Mouse protocols were approved by the Johns Hopkins University Animal Care and Use Committee. We performed caliper measurements of the longest perpendicular tumor diameters every other day. We estimated tumor volume according to the formula for a three dimensional ellipse: 4p / 3 Â (width / 2) 2 Â (length / 2). We performed treatment and imaging studies when tumors reached a size of B1 cm in diameter.
Ex vivo biodistribution. As previously described 7 , we injected [ 125 I]FIAU in PBS into the tail vein, killed three or four mice at each indicated time point, removed and weighed organs and measured tissue radioactivity with an automated g counter. We calculated the percentage injected dose per gram of tissue by comparison with samples of a standard dilution of the initial dose.
Planar c imaging, single-photon emission computed tomography and image analysis. As previously described 7 , we performed imaging as an adjunct to the ex vivo biodistribution studies. The X-SPECT (Gamma Medica Instruments) has a g-ray detector head dimension of 20.5 Â 15 Â 9 cm and a field of view of 120 Â 125 mm. The high-resolution parallel hole collimator has the following specifications: 1.22-mm hole diameter, 0.20-mm septa thickness and 25.4-mm bore hole length. The detector material composed of NaI[Tl] has a pixel size of 2 Â 2 Â 6 mm. We placed mice in a prone position on the parallel hole collimator and kept them under anesthesia with isoflurane. We obtained 10-min high-resolution scans of each mouse. We performed SPECT with the above-mentioned g-ray detector and the computed tomography detector sequentially without removing the mouse from the gantry. We performed analysis of imaging data with ImageJ v1.30 (US National Institutes of Health) 
